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Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identified as frequently altered in lung
cancer. LKB1, a kinase inactivated in 30% of lung cancers, is discussed in this review. Loss of LKB1 regulation often coincident with
KRAS activation allows for unchecked growth and the metabolic capacity to accommodate the proliferation.
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HERITABLE TUMOUR SYNDROMES AND LUNG
CANCER
Heritable tumour syndromes have provided invaluable insights
into human disease. These focal perversions of normal growth and
development shine as a beacon on particular genes and pathways
in a manner, which, once deciphered, can impact far beyond the
heritable syndrome itself. Just as a jigsaw puzzle assembled in
parts suddenly comes together when a key piece is recognised, the
genetic syndrome can bring together vastly disparate biologic
knowledge to yield a bit of clarity where none existed before.
Although the field of lung cancer has lacked such a fortuitous
discovery to date, a series of recent events appears likely to open a
new era in our understanding of the disease. Three genetic
syndromes, Peutz–Jeghers syndrome (PJS), Cowden’s disease
(CD), and tuberous sclerosis (TS), all sharing parallel phenotypes
primarily of non-malignant and non-pulmonary disease, have
crystallised a common pathway, which is activated in a significant
proportion of all human lung cancers. Key pieces have been
identified and joined, such as nutrient metabolism, proliferative
signalling, and anti-apoptosis pathways. The puzzle of lung
tumour genesis, invasion, and metastasis is somewhat more
complete.
LKB1 AND PJS
The central figure in the current discussion is the gene LKB1. Its
discovery as well as an appreciation of its biology is dominated by
its causative role in the autosomal-dominant inherited PJS. First
described in the 1920s by Johannes Peutz, an association with
cancer was made by Harold Jeghers in the 1940s (Peutz, 1921;
Jeghers et al, 1949). The syndrome includes an overgrowth of
differentiated tissues called hamartomas, primarily polyps in the
gastrointestinal tract (GI), as well as abnormal pigmentation of the
mucous membranes and skin. Validating Dr Jegher’s observations,
large cohorts have clarified the risk and spectrum of malignancies
in PJS, including a cumulative cancer risk of 60% by the age
60 years (Hearle et al, 2006). Of primary concern for PJS patients
are tumours of GI origin, although breast, gynaecologic, pancreas,
and lung have been reported.
The pattern of inheritance of PJS, as well as the high frequency
of cancer in affected, indicated that a tumour suppressor gene was
likely the causative agent. In 1997, Hemminki et al (1997)
identified the chromosome region 19p13.3 as the relevant
cytoband. A year later a single gene called serine/threonine kinase
11 (STK11) was identified as the culprit (Hemminki et al, 1998;
Jenne et al, 1998). The transcript for STK11 had previously been
reported in an unmapped fashion by the more commonly used
gene alias LKB1. The identification of a tumour suppressor and its
genomic coordinates inspired a flurry of tumour resequencing
surveys of LKB1 in a range of tissues. Table 1 reviews a sample of
the largest of these reports in the area of lung cancer, and includes
associated epigenetic findings. Although infrequently mutated
in spontaneous tumours, LKB1 point mutations were seen in a
pattern mirroring those seen in association with PJS, including
cervix, gastrointestinal, and pancreas (Avizienyte et al, 1999;
Sanchez-Cespedes, 2007). A range of atypical PJS tumours was also
identified, including prostate and melanoma. Surprisingly, the
highest mutation rate, hovering around 25% in multiple studies,
was in lung adenocarcinomas, an established but uncommon PJS-
associated tumour (Virmani et al, 1998; Sanchez-Cespedes et al,
2001) (Table 1).
LKB1 LOSS IN CANCER
The LKB1 locus had been previously indicated as important in
lung cancer, although admittedly without the laser focus of a
known genomic syndrome and target gene. Indeed, 19p13.3 has
been repeatedly indicated for its high frequency of loss of
heterozygosity (LOH), often above 50%, in lung cancer by
chromosomal analysis (Sobottka et al, 2000). Interestingly, the
frequency of LOH for many tumours, including lung cancer,
continues to be significantly higher than the reported rate of point
mutations. The discrepancy between the reported rate of mutation
and LOH raises a number of questions, including the accuracy of
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of gene silencing (such as, promoter methylation or other
epigenetic event), or the possibility that a second gene target lies
in the region. In fact, careful attention to resequencing is crucial,
and techniques that detect large homozygous deletions are
required to fully characterize tumour LKB1 loss (Ji et al, 2007).
Yet, thorough sequencing alone does not fully account for the LOH
mutation frequency discrepancy, prompting investigators to
pursue other mechanisms of gene silencing. Promoter methylation
accounts for a small fraction of repressed LKB1 expression cases,
but this is unlikely a major contributing mechanism (Esteller et al,
2000; Trojan et al, 2000). Other mechanisms of gene silencing,
including microRNA, might contribute to some of the gap but
these remain under investigation. Perhaps, the most interesting
possibility is that LKB1 haploinsufficiency itself could be tumori-
genic, as we have recently shown in animal models (Ji et al, 2007).
At this time, however, we cannot exclude the possibility that there
is another gene target in the 19p13.3 region that could account for
additional cases of LOH, such as BRG1 (Medina et al, 2008). In
contrast to the challenges of detecting functional LKB1 gene dosage
described above, two authors have reported that immunohisto-
chemical assessment of LKB1 protein status as a straightforward
proxy for both biallelic loss and promoter methylation (Ghaffar
et al, 2003; Fenton et al, 2006). Taken together, information on
genetic status of LKB1 garnered through examining PJS patients
and screening multiple tumour types has pointed to LKB1 as an
important mediator in the development of cancer.
Frequent LOH at 19p13.3 points only indiscriminately to the
importance of the LKB1 locus in lung cancer, as many regions have
chromosomal alterations in this disease. Similarly, the dramatic
Table 1 Summary results of studies reporting LKB1 mutation and other related events in lung cancer
Reference Year Finding Method Comments/observations
Virmani et al
(1998)
1998 10/12 LOH in NSCLC cell lines and 3/9 in SmCC
cell lines in 19p13.2
Allelotyping by PCR Lung cancer cell lines used to define common,




2000 7/12 (58%) patients with LOH at 19p in brain
metastases of lung cancer patients, whereas
glioma LKB1 LOH was o20%
Microsatellite PCR analysis
and genomic sequencing
None of brain metastases showed LKB1 mutations
by direct genomic sequencing
Sanchez-Cespedes
et al (2002)
2002 5/20 of primary AC, 0/12 primary SCC; and





0/12 mutations in SCC
1/20 tumor with LKB1 promoter hypermethylation Methylation-specific PCR
Ghaffar et al (2003) 2003 9/35 loss of LKB1 protein in AC, 10/96 loss in
AAH (7/33 loss in high-grade AAH; 3/63 loss
in low grade; 9/35 invasive tumors)
Immunohistochemistry LKB1 protein loss from AAH correlated with
severe dysplasia, suggesting loss as essential to
transition from pre- to malignant tumor. Also
showed strong positive association between




2004 5/19 lung AD with point mutations of LKB1 Direct sequencing,
long-range PCR
Frequent observation of concurrent KRAS (4/11)
and p53 (6/11) in LKB1 mutant samples. Performed
microarray analysis with several genes dependent
on LKB1 status
0/19 samples with promoter methylation of LKB1 Methylation-specific PCR












2007 Lung cancer cell lines with mutations in LKB1:




Strong positive correlation with KRAS status, not
correlation with p53 status or EGFR mutation status
8/70 lung cancer cell lines demonstrated shortened
LKB1 transcripts, 9/70 demonstrated absent
LKB1 transcript
Two cell lines with absent gene expression did not
demonstrate mutation, suggesting alternate gene
silencing method. The 9/70 with loss of LKB1 had
deletions in promoter or exon 1
Primary tumors: 1/106 stage 1 tumor with LKB1
mutation, 3/24 stages I–III. 7/91 male smokers,
0/64 female non-smokers
Small numbers limit interpretation for KRAS and
EGFR associations, appears to be associated with
poorly differentiated tumors
3/25 brain metastases of lung cancer patients
with LKB1 mutation
Ji et al (2007) 2007 Primary tumors: 19/80 AD, 6/42 SCC, 1/7 LCC,
and 1/4 ADSCC, respectively, with single copy






SCC, AD, SCC, LCC, and AD: frequent loss of a




2007 Cell lines with mutations in LKB1: 3/8 AD,
1/6 SCC, 1/3 LCC, and 0/5 SmCC
Direct sequencing Lung cancer cell lines examined
3/100 primary tumors with LKB1 mutations
in Japanese cohort 3/33 male smokers
Direct sequencing LKB1 mutation rare in Japanese lung cancer
population. All mutations were in male smokers
with moderately or poorly differentiated tumors
ADSCC¼adenosquamous carcinoma; AD¼adenocarcinoma; AAH¼atypical adenomatous hyperplasia; LCC¼large cell carcinoma; LOH¼loss of heterozygosity;
NSCLC¼non-small-cell lung cancer; PCR¼polymerase chain reaction; SmCC¼small cell carcinoma; SCC¼squamous cell carcinoma.
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but not at such a high rate as to suggest the prevalence of LKB1
alteration in this tumour (Hirano et al, 2002; Estrada Trigueros
et al, 2005; von Herbay et al, 2005). Yet, cancers in a few young
patients with PJS, indeed, suggest a role as a potential early
carcinogenic event. Ghaffar et al (2003) have bolstered this
possibility by detecting frequent LKB1 loss in the progression of
the premalignant lesion atypical adenomatous hyperplasia (AAH)
towards frank invasive. Developmentally, LKB1 is expressed in
foetal lung and ubiquitously expressed in adult bronchial mucosa,
underscoring its importance in normal lung physiology and
development (Luukko et al, 1999). Step by step, pieces of a puzzle
assemble to document both the importance of LKB1 to the normal
lung and its high frequency of aberrancy in cancer. Yet, the reader
might still rightfully wonder why does a gene that primarily causes
genetic disease of the gut appear to be mutated so early and often
in sporadic cases of lung cancer?
LKB1 EXPRESSION, REGULATION, AND ACTION
Like individual pieces of a jigsaw puzzle, the various facets of LKB1
need further consideration before they reveal a coherent picture.
The functional domains of LKB1’s 10 exons (9 coding) include a
central catalytic domain, nuclear localisation signal, putative
cytoplasmic retention signal, and a prenylation motif (Alessi
et al, 2006). Localised to the nucleus, it is transported to the cytosol
and activated by binding two associated proteins STE20-related
adaptor (STRAD), a catalytically inactive kinase-like protein, and
an armadillo repeat-containing protein named mouse protein 25
(MO25). The complex is 100-fold more active as a kinase than
LKB1 alone. LKB1 also associates with a chaperone complex
consisting of HSP90 and Cdc37, which likely aids in stabilisation of
LKB1 protein and assembly of the STRAD–MO25 complex. LKB1
is phosphorylated on several sites, either activating or inhibiting,
by several kinases, including p90 ribosomal S6 kinase (RSK),
protein kinase A (PKA), or ataxia-telengiectasia-mutated (ATM)
kinase. Despite the apparently rich regulatory aspects of LKB1,
however, no mutation hot spots have emerged.
LKB1 functions as a tumour suppressor that regulates cell
polarity, differentiation, and metastasis as well as responds to
energy status to regulate cell metabolism (Figure 1) (see Alessi
et al, 2006; and references within). One function of LKB1 directly
linked to lung cancer is the phosphorylation, ubiquitination, and
the degradation of polyomavirus enhancer activator 3 (PEA3).
Mutant LKB1 increases the stability of PEA3, which, in turn,
increases transcription of genes involved in metastasis, including
COX-2, MMP-9, and MMP-14 (Upadhyay et al, 2006; Cowden Dahl
et al, 2007). Interestingly, COX-2 is commonly elevated in many
disease states, including PJS and lung cancer (Achiwa et al, 1999;
Rossi et al, 2002; McGarrity et al, 2003). Indeed, COX-2 inhibition
decreased polyps in a small study of PJS patients and a large study
of patients with familial adenomatous polyposis (Udd et al, 2004;
Bertagnolli et al, 2006). Finally, increased COX-2 is associated with
decreased survival in patients with lung adenocarcinoma (Achiwa
et al, 1999). Although LKB1 clearly regulates proteins such as
PEA3, current understanding is that its primary action is through
the target 50-AMP-activated protein kinase (AMPK) (Towler and
Hardie, 2007). AMPK is a master regulator of metabolism that
orchestrates efficient energy production with minimal waste
in times of energy stress. It is a serine/threonine kinase activated
by metabolic signals and stressors, including exercise, starvation,
hypoxia, and ischaemia. In short, consumption of ATP, decreased
ATP production, and/or increased concentration of AMP activate
AMPK to alter numerous metabolic and proliferative pathways
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PTEN TSC1-TSC2 RhebGTP
Insulin/growth factors PI3K PIP3 AKT
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ACC malonyl CoA CPT-1 Fatty acid oxidation
+
Increased AMPK-mediated catabolic pathways
PGC1alpha Mitochondrial biogenesis & activity
+
Gluconeogenesis TORC2 PEPCK, G6P
HMGCR Cholesterol synthesis
ACC1, FAS Fatty acid synthesis SREBP, HNF-4
Decreased AMPK-mediated anabolic pathways
GS Glycogen synthesis
Figure 1 Energy sentinels in proliferation: LKB1 and AMPK. LKB1 is activated by binding STRAD and MO25. AMPK is a master regulator of metabolism,
which is activated by LKB1 phosphorylation when the AMP/ATP ratio is high. AMPK drives catabolic pathways such as glucose uptake, glycolysis,
mitochondrial proliferation, and fatty acid oxidation to generate ATP in times of stress. It also blunts ATP-consuming anabolic pathways including fatty acid,
cholesterol, glycogen, and protein synthesis. The latter role of inhibiting protein synthesis through TSC1/2 and mTOR underlie AMPK’s role in cell growth
and proliferation. However, LKB1–AMPK regulation of fuel availability and the metabolic status is also central to proliferation. In fact, the LKB1 signal that
cells should halt division when sufficient nutrients are not present overrides growth factor signalling through EGFR, for example. In sum, LKB1 and AMPK act
together to sense energy stress to provide cells with nutrients for rapid energy production, while limiting growth. The sentinel activity of LKB1 and AMPK is
lost in cancer, which allows unlimited proliferation despite metabolic cues to the contrary.
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scarce, AMPK ensures ATP generation by activating catabolic
pathways such as glycolysis and fatty acid oxidation, as well
as upregulates mitochondrial biogenesis. In parallel, it switches
off ATP-consuming anabolic pathways, including fatty acid,
cholesterol, glycogen, and protein synthesis. Of relevance to this
review, AMP binding to AMPK only causes a fivefold increase in
activity, while the AMP-induced conformational change in AMPK
primes it as a substrate for LKB1, allowing LKB1 phosphorylation
to induce activation by 100-fold (Alessi et al, 2006). Therefore,
AMPK action and LKB1 activity are tightly coordinated to sense
energy stress and attempt to provide cells with fuel for rapid
energy production, while limiting growth and energy loss when
nutrients are scarce.
LKB1 PROLIFERATION, METASTASIS, AND
METABOLISM
A central target for AMPK’s control of proliferation is the
mammalian target of rapamycin (mTOR) kinase, which regulates
numerous downstream targets, such as amino acid transporters,
VEGF, p70 ribosomal protein S6 kinase 1 (S6K), and eukaryotic
initiation factor 4E-binding protein 1 (4E-BP1) pathways, among
others, to increase the translation of proteins and cell growth
(Figure 1). In fact, AMPK acts on mTOR through phosphorylating
and activating tumour suppressor tuberous sclerosis complex-2
(TSC2), an upstream negative regulator of mTOR. AMPK
activation also blocks cell cycle progression from G1 to S phase
through phosphorylation and accumulation of the tumour
suppressor p53 and the downstream cyclin-dependent kinase
inhibitors p21
WAF1/CIP1 and p27. Other cell cycle regulation occurs
through the alteration of cytoplasmic/nuclear ratios of RNA-
binding protein human antigen R (HuR), thereby reducing the
ability to stabilise mRNAs encoding cyclins (Wang et al, 2002).
Finally, hypoxia-induced AMPK activation of endothelial NOS
(eNOS) drives angiogenesis. The relative importance of each
mechanism discussed remains to be determined. In sum, LKB1
inactivation in cancer releases the AMPK-mediated breaks on
energy waste and permits proliferation. The capacity to sense a
nutrient deficit is a function of healthy cells that is lost in
proliferating cells, which highlights a distinctly separate but
parallel piece of the cancer puzzle.
HAMARTOMATOUS SYNDROMES, mTOR,
AND LUNG CANCER
Decoding the regulatory networks of LKB1, particularly an
interaction with the AMPK–mTOR axis, crystallises a link between
a genetic disease with little pulmonary implications and a gene
frequently altered in lung cancer. Clearly, mTOR is a lung cancer
target; yet, the jumble of alternate pathways raises doubts as to
whether this is the primary mechanism (Figure 1). Quite
remarkably, upstream of the mTOR pathway, however, is the
invocation of three genes and two autosomal-dominant inherited
syndromes with phenotypes remarkably similar to PJS, including
PTEN (CD) and TSC1/TSC2 (tuberous sclerosis, TS). Like PJS, both
CD and TS manifest themselves as primary hamartomatous
diseases. Patients with CD demonstrate hamartomas of the skin,
mucous membranes, breast, and thyroid, with 85% of patients
showing PTEN germline mutation. Like PJS, an increased risk of
tumours is seen, although again lung cancer is not prominent. The
PTEN phosphatase controls the levels of PIP3 induced by growth
factor activation of PI3 kinase, and acts to negatively regulate
mTOR activity. Patients with TS do not have malignancy as their
primary concern, but instead hamartomas of the skin, brain,
kidney, skin, lungs, and other tissues (Crino et al, 2006). As in CD,
the TS complex acts as a negative regulator of mTOR. In summary,
the related phenotypes of PJS, CD, and TS are joined by shared
regulation of the mTOR signalling cascade.
Consideration of these syndromes begs the question, is there a
broader lung cancer malignant phenotype equivalent to that
shared by germline PJS, CD, and TS? In fact, mutations of PTEN
have been reported in many tumours, including 4–8% of non-
small-cell lung cancers (NSCLC) (Forbes et al, 2006). PTEN protein
expression is lost in more than 25% of NSCLC tumours with
evidence of epigenetic silencing at work as well (Luukko et al,
1999; Marsit et al, 2005). Additionally, PTEN is co-expressed with
LKB1 in foetal lung development. Similarly, both the TSC1 locus
(9q34) and the TSC2 locus (16p) are frequent targets of LOH in
both lung adenocarcinoma and the pre-invasive lung lesion AAH
(Takamochi et al, 2001, 2004). Although the frequency with which
these events occur in concert remains unknown, the conclusion
must be that targets coalescing on the mTOR pathway defined in
large part by dissecting the disease of germline mutations of LKB1,
PTEN, and TSC1/2 appear to be frequently altered in lung cancer,
suggesting a broad and important contribution of this specific set
of interacting proteins to the disease.
TURNING TO ANIMAL MODELS: LKB1 AND KRAS
Recent years have seen progress similar to that we document for
LKB1 in a number of other lung cancer genes and cancer networks,
such as EGFR, KRAS, p53, and CDKN2A (including both
transcripts: p16
Ink4a and INK4a/ARF). As we suggest above, it is
expected that the alteration of only one gene in a pathway may be
sufficient for tumorigenesis. As such, an understanding of the
relationships between aberrations may help clarify the minimal set
of events necessary to cause cancer. To this end, we documented
several interactions between LKB1 and other genes commonly
altered in lung cancer in experimental animal models (Ji et al,
2007). As predicted from the natural human experiment of PJS,
mice deficient in LKB1 do not get lung tumours. The alteration of
other lung cancer genes in combination with LKB1, however, did
produce tumours of a striking phenotype. First, we observed that
homozygous loss of LKB1 in combination with KRAS resulted in
an aggressive tumour phenotype with high tumour multiplicity,
short survival, and frequent metastases well above those of KRAS
alone. The KRAS/LKB1 double knockout was in fact the most
aggressive phenotype of all tumours considered in the study, and
had an additional feature that had not previously been reported in
a mouse model: squamous cell carcinoma histology. Additionally,
it was noted that even hemizygous loss of LKB1 in combination
with KRAS resulted in a more aggressive phenotype than in KRAS
mutation alone.
The clinical relevance of LKB1 alteration remains an area of
active investigation, although preliminary results appear likely to
confirm findings of the animal models, including the frequent co-
mutation of LKB1 inactivation and activating mutations of KRAS
(Table 1). As a mirror opposite to the established positive
association of EGFR gene mutation with females and nonsmokers,
we detect a positive association of LKB1 inactivation with both
smoking and male gender. Other interesting reports, including
prevalence of brain metastasis, associations with poorly differ-
entiated tumours, the importance of the hemizygous LKB1 state,
and apparent independence with p53 mutation, remain to be
confirmed. Certainly, we hope for clinical associations of this type
on which to base important patient management decisions. In
broader terms, one has to note that many of the tumours
associated with PJS, including GI and gynaecologic malignancies
are also those where KRAS is a frequent target of mutation. The
question remains, is the LKB1–KRAS connection part of a broad
phenotype of interconnecting cancer pathways? We propose that
perhaps KRAS activation and LKB1 loss permit liberation from cell
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metabolic advantage.
mTOR AND KRAS IN THE CLINIC
Paramount in the LKB1 story is the focus now thrust upon
very specific cancer pathways, several of which have attractive
therapeutic targets. At the top of the list is the mTOR pathway
where three Food and Drug Administration (FDA)-approved
inhibitors are currently available, such as rapamycin, everolimus,
and temsirolimus, with more in development, including the
recently described deforolimus (Cohen, 2008). Inhibitors of mTOR
have already been investigated in lung cancer, with clear evidence
of anticancer activity both as single agents and in combination
with cytotoxic chemotherapy and radiation (Milton et al, 2007;
Sarkaria et al, 2007; Mita et al, 2008). Interestingly, a recent report
in the New England Journal of Medicine documented a striking
therapeutic effect of mTOR-targeted therapy by sirolimus to
angiomyolipomas, which are lesions attributable to TSC dysfunc-
tion in patients with TS (Bissler et al, 2008). Patients with
angiomyolipomas, including the pulmonary form lymphangioleio-
myomatosis, almost uniformly experienced reduction in the size of
their tumours with this therapy. The efficacy of mTOR-targeted
therapy in this benign tumour of the lung, marked by one aspect of
mTOR activation, certainly is of interest due to its parallel biology
in lung cancer.
Although activity in these early studies has been documented,
there is little evidence that this will be of a broader spectrum than
for other classes of lung cancer therapeutics. Therefore, there is an
incentive to define biomarkers of response to therapy, such as
mutation status or, perhaps, more encompassing markers such as
those indicating AMPK activity. There is increasing evidence that
broad patterns of tumour behaviour can be captured as general
phenotypes using profiling techniques such as gene expression
arrays. Specifically, the squamoid gene expression subtype of lung
adenocarcinoma is known to have higher rates of KRAS mutation
and demonstrates gene expression correlated with LKB1 inactiva-
tion (Hayes et al, 2006). It is also interesting to note that as LKB1
mutation appears to pair with KRAS activation, specific combina-
tions of therapy targeting parallel pathways might be appropriate.
Indeed, initial work on this similar line has begun, including
targeting downstream elements of RAS signalling (MEK) and
mTOR simultaneously (Legrier et al, 2007).
CONCLUSION
Three phenotypically related genetic syndromes, including PJS,
CD, and TS, are united by careful alignment of their mechanisms
acting through the mTOR pathway. The lesions responsible for the
syndromes, LKB1, PTEN, and TSC1/2, are identified as frequently
altered in lung cancer, suggesting that they comprise elements
of a common lung caner phenotype. Taken together, when the
phenotype of LKB1 mutation is examined in the setting of known
alterations of lung cancer, an interesting association of KRAS
dependence appears, with specific clinical and treatment potential.
Like all good puzzles, the pieces are starting to fall into place.
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